Sickle Cell Disease School Resources

Introduction

Useful Links

Helpful Videos

Unesco World Sickle Cell Day Declarition Poster

Unesco World Sickle Cell Day Declarition Poster

Useful PDF Resources

Introduction

The Sickle Cell Awareness Group of Ontario (SCAGO) in collaboration with various stakeholders continues to support schools in Ontario. Working closely with schools is essential given that students living with sickle cell disease must be encouraged to excel academically.

Resources available for schools
In-school training
in-school support for staff, educators, parents, and students
Online videos and webinars
conferences and seminars

Useful Links

About Kids Health

Helpful Videos

Sickle Cell Awareness in Schools
This video provides more awareness and education on the subject of sickle cell disease. It is important to use this video when training school educators and staff.

World Sickle Cell Day in Schools
This video provides more awareness and education on the subject of sickle cell disease. It is important to use this video when training school educators and staff.

For educational videos on various topics relating to Sickle Cell Disease, visit our YouTube channel.

Unesco World Sickle Cell Day Declarition Poster

Useful PDF Resources

Click the PDF links to read or download them:

Articles

Discover other Patient & Caregivers Articles

SCAGO

Vaccine Equity Studies in Sickle Cell Disease

Read the results of the vaccine equity study in Sickle Cell Disease conducted by SCAGO, funded by the Public Health Agency of Canada

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.